Literature DB >> 12446512

Improving the management of acute myocardial infarction.

Mark W Savage, Kevin S Channer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12446512      PMCID： PMC1124676          DOI： 10.1136/bmj.325.7374.1185

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

Review 1.  Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis.

Authors:  M A Sloan; J M Gore
Journal:  Am J Cardiol       Date:  1992-01-03       Impact factor: 2.778

Review 2.  Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies.

Authors:  C L Grines; A N DeMaria
Journal:  J Am Coll Cardiol       Date:  1990-07       Impact factor: 24.094

3.  ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors:  C Baigent; R Collins; P Appleby; S Parish; P Sleight; R Peto
Journal:  BMJ       Date:  1998-05-02

4.  Safety and efficacy of nurse initiated thrombolysis in patients with acute myocardial infarction.

Authors:  Asif Qasim; Kerry Malpass; Daniel J O'Gorman; Mary E Heber
Journal:  BMJ       Date:  2002-06-01

5.  Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial.

Authors:  B W Böttiger; C Bode; S Kern; A Gries; R Gust; R Glätzer; H Bauer; J Motsch; E Martin
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

6.  Reperfusion therapy for acute myocardial infarction: observations from the National Registry of Myocardial Infarction 2.

Authors:  H V Barron; A Rundle; J Gurwitz; A Tiefenbrunn
Journal:  Cardiol Rev       Date:  1999 May-Jun       Impact factor: 2.644

7.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

8.  Strict reliance on a computer algorithm or measurable ST segment criteria may lead to errors in thrombolytic therapy eligibility.

Authors:  D Massel; J A Dawdy; L J Melendez
Journal:  Am Heart J       Date:  2000-08       Impact factor: 4.749

9.  Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years.

Authors:  D R Thiemann; J Coresh; S P Schulman; G Gerstenblith; W J Oetgen; N R Powe
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

10.  Perceived contraindications to thrombolytic treatment in acute myocardial infarction. A survey at a teaching hospital.

Authors:  D S Wald
Journal:  J Accid Emerg Med       Date:  1998-09
View more
  1 in total

1.  Checklists for myocardial infarction should be precise.

Authors:  G Alastair Cooke
Journal:  BMJ       Date:  2003-02-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.